Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trialKazuhiko Nakagawa, Katsuyuki Hotta, Edward B. Garon et al.|The Lancet Oncology|2019Cited by 617
Treatment of Pleural Mesothelioma: ASCO Guideline UpdateHedy L. Kindler, Raffit Hassan, Nofisat Ismaila et al.|Journal of Clinical Oncology|2025Cited by 55
A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancerAlberto Chiappori, M. S. Berger, Marshall T. Schreeder et al.|British Journal of Cancer|2012Cited by 51
A phase Ib trial of Bcl-2 inhibitor obatoclax in combination with carboplatin and etoposide for previously untreated patients with extensive-stage small cell lung cancer (ES-SCLC)Alberto Chiappori, M. S. Berger, Marshall T. Schreeder et al.|Journal of Clinical Oncology|2009Cited by 11
Efficacy and CNS results from a randomized subset of the phase 2 SAVANNAH study comparing savolitinib (savo) + osimertinib (osi) combination with savo + placebo (PBO).Benjamin Levy, Myung‐Ju Ahn, James C. Yang et al.|Journal of Clinical Oncology|2025Cited by 4